Zerbaxa

Zerbaxa

Manufacturer:

MSD

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ceftolozane 1 g, tazobactam 0.5 g
Indications/Uses
Infections caused by susceptible microorganisms in complicated intra-abdominal infections in combination w/ metronidazole; complicated UTI, including pyelonephritis & nosocomial pneumonia, including ventilator-associated pneumonia.
Dosage/Direction for Use
IV infusion Adult ≥18 yr Complicated intra-abdominal infection 1.5 g every 8 hr for 4-14 days in combination w/ metronidazole 500 mg IV every 8 hr. Complicated UTI including pyelonephritis 1.5 g every 8 hr for 7 days. Renal impairment 30-50 mL/min 750 mg every 8 hr, 15-29 mL/min 375 mg every 8 hr. ESRD on hemodialysis 750 mg as single loading dose followed by 150 mg every 8 hr as maintenance dose for the remainder of the treatment period. Nosocomial pneumonia including ventilator-associated pneumonia 3 g every 8 hr for 8-14 days. Renal impairment 30-50 mL/min 1.5 g every 8 hr, 15-29 mL/min 750 mg every 8 hr. ESRD on hemodialysis 2.25 mg as single loading dose followed by 450 mg every 8 hr as maintenance dose for the remainder of the treatment period.
Contraindications
Hypersensitivity to ceftolozane & tazobactam, or to any cephalosporin antibacterial agents. Severe hypersensitivity eg, anaphylactic, severe skin reaction to any other type of β-lactam antibacterial eg, penicillins or carbapenems.
Special Precautions
Previous hypersensitivity reactions to other cephalosporins, penicillins, or other β-lactams; cross sensitivity. Discontinue if anaphylactic reaction; Clostridium difficile-associated diarrhea occurs. Risk of developing drug-resistant bacteria. Decreased efficacy in patients w/ baseline CrCl of 30 to ≤50 mL/min. Frequently monitor patients w/ renal impairment.
Adverse Reactions
Anemia, thrombocytosis; atrial fibrillation; abdominal pain, constipation, diarrhea, nausea, vomiting; infusion site reactions, pyrexia; increased ALT & AST; hypokalemia; dizziness, headache; anxiety, insomnia; rash; hypotension. Clostridium difficile colitis; increased transaminases.
Drug Interactions
Increased tazobactam plasma conc & prolonged t½ w/ OAT1/OAT3 inhibitor eg, probenecid.
MIMS Class
Cephalosporins
ATC Classification
J01DI54 - ceftolozane and beta-lactamase inhibitor ; Belongs to the class of other cephalosporins and penems. Used in the systemic treatment of infections.
Presentation/Packing
Form
Zerbaxa inj 1.5 g
Packing/Price
10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in